Professor Udai Banerji22 Feb 2023 10:20
Banerji described a range of methods for targeting cancer cells and explained how Avacta’s lead pre|CISION drug candidate, AVA6000, currently in a Phase I trial to treat soft tissue sarcoma, is DIFFERENT. According to Banerji, AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using pre|CISION technology.
Preclinical data from AVA6000 is positive and on the strength of this, Avacta opened an IND with FDA in November 2021 in addition to FDA granting AVA6000 orphan drug status in September 2022.